Literature DB >> 8730252

One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection.

J Labenz1, M Stolte, U Peitz, B Tillenburg, T Becker, G Börsch.   

Abstract

AIM: The present study was designed to evaluate the efficacy and tolerability of 1-week triple therapy regimens for Helicobacter pylori.
METHODS: In two consecutive series, 120 patients with proven H. pylori infection and peptic ulcer disease or functional dyspepsia were treated with either omeprazole 20 mg b.d., amoxycillin 1 g b.d. and clarithromycin 250 mg b.d. (OAC; n = 60) or with omeprazole 20 mg b.d., amoxycillin 1 g b.d. and metronidazole 400 mg b.d. over 1 week (OAM; n = 60). H. pylori infection was assessed by rapid urease test, culture and histology before and 4 weeks after cessation of the eradication therapy.
RESULTS: H. pylori eradication succeeded in 53 out of 60 patients by omeprazole-amoxycillin-clarithromycin (OAC) (88%; 95% CI 77-95%) and in 47 out of 60 patients by omeprazole-amoxycillin-metronidazole (OAM) (78%; 95% CI 66-88%) (P = 0.22). Nine patients of each group available for follow-up reported adverse events (15.0 and 15.5%, respectively) without necessity of discontinuation of the study medications. Serious adverse events were not observed.
CONCLUSIONS: Simple and convenient 1-week triple therapies consisting of omeprazole, amoxycillin and either clarithromycin or metronidazole are sufficiently effective in eradicating H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730252     DOI: 10.1046/j.1365-2036.1996.727119000.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

Review 1.  Helicobacter pylori.

Authors:  M C Bateson
Journal:  Postgrad Med J       Date:  2000-03       Impact factor: 2.401

2.  Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy.

Authors:  Izumi Shimbo; Taketo Yamaguchi; Takeo Odaka; Kenichi Nakajima; Akinori Koide; Hidehiko Koyama; Hiromitsu Saisho
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

3.  One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group.

Authors:  J J Misiewicz; A W Harris; K D Bardhan; S Levi; C O'Morain; B T Cooper; G D Kerr; M F Dixon; H Langworthy; D Piper
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

4.  [Short-term triple therapy with pantoprazole, amoxicillin and metronidazole in Helicobacter pylori infection].

Authors:  J Glaser; J Hein; R Daikeler; G Weithofer; M Vieth; M Schmidt; M Stolte
Journal:  Med Klin (Munich)       Date:  1998-02-15

5.  Dual versus triple therapy of Helicobacter pylori infection: results of a multicentre trial.

Authors:  R Behrens; T Lang; K M Keller; L Bindl; M Becker; B Rodeck; P Küster; G F Wündisch; M Stolte
Journal:  Arch Dis Child       Date:  1999-07       Impact factor: 3.791

6.  Treatment of Helicobacter pylori: future therapeutic and prophylactic perspectives.

Authors:  A T Axon
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

Review 7.  Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

8.  Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori.

Authors:  Engin Altintas; Orhan Sezgin; Oguz Ulu; Ozlem Aydin; Handan Camdeviren
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.